Keywords: SkyePharma, Kyorin, Flutiform, Japan clinical program, Regulatory filing

SkyePharma partner Kyorin completes Japanese Flutiform clinical program

Article | 26 June 2012

Print This

UK drug delivery specialist SkyePharma (LSE: SKP) saw its shares leap nearly 11% to £76.50 last week, after the company announced ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in